RHYTHM PHARMACEUTICALS INC

Rhythm Pharmaceuticals’ CTO uses a Rule 10b5‑1 plan to buy low, sell high, and exercise options—showing disciplined insider confidence amid breakthrough NASH therapy progress.

Lee Kayden’s 10b‑5‑1 buys show insider confidence in Rhythm Pharma’s obesity/diabetes pipeline and potential upside toward a $122.20 peak.

Rhythm Pharmaceuticals’ CEO buys 4,712 shares, boosting insider confidence and spiking social‑media buzz—signals a bullish outlook amid a growing metabolic‑disorder market.

Rhythm Pharmaceuticals’ insider trading shows executive confidence in obesity/diabetes programs, with strategic buys and profit‑taking reflecting disciplined equity management and growth potential.

Insider buying at Rhythm Pharmaceuticals signals confidence amid market volatility: the Mathers Trust’s zero‑cost acquisition hints at long‑term optimism, especially as the company’s obesity pipeline nears key milestones.

Rhythm Pharmaceuticals insider buying signals confidence: EVP Yann Mazabraud buys 35 k zero‑price options amid volatile biotech market, FDA scrutiny, and growth prospects. Click for insights.

Mathers’ recent insider purchase of Rhythm Pharmaceuticals stock signals confidence in the company’s setmelanotide pipeline and potential multi‑billion‑dollar revenue. Discover why this bullish move matters for investors.

Insider buys 1,162 RSUs at Rhythm Pharmaceuticals, boosting confidence in its setmelanotide obesity drug and FDA filing—key signals for investors.

Rhythm Pharmaceuticals CFO buys shares, boosting optimism for setmelanotide and bivamelagon’s Phase‑3 prospects amid a bullish biotech rally.

Insider selling at Rhythm Pharmaceuticals: CFO’s Rule 10b5‑1 sales show systematic liquidity, not loss of confidence—what this means for investors and valuation.